Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia.

Abstract

Glycogen synthase kinase-3 (GSK-3) is a downstream component of the Wnt pathway and recent studies have reported abnormal levels of GSK-3beta in schizophrenia. In a sample of 147 schizophrenic patients and 212 healthy individuals, we analyzed two common SNPs at position -1727 A/T and -50 C/T and a (CAA)(n) repeat polymorphism localized in intron 1 of the gene. The results showed that the allele, genotype and haplotype distributions for the three polymorphisms investigated do not differ between schizophrenic patients in general and control subjects. However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)(3)/(CAA)(5) heterozygotes were more often represented. Although taken from a small sample, our results support the reports that GSK-3beta appears to be involved in a subtype of schizophrenic patients, but not in schizophrenia in general. In conclusion, we would speculate that this gene may be linked to some features of psychotic disorders rather than to schizophrenia itself.

• Authors: Catia Scassellati, Cristian Bonvicini, Jorge Perez, Luisella Bocchio-Chiavetto, Gian Battista Tura, Giuseppe Rossi, Giorgio Racagni, Massimo Gennarelli
• Journal: Neuropsychobiology (Neuropsychobiology) Vol. 50 Issue 1 Pg. 16-20 ( 2004) ISSN: 0302-282X [Print] Switzerland
• PMID: 15179015 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2004 S. Karger AG, Basel

Chemical References

• GSK3B protein, human
• Glycogen Synthase Kinase 3 beta
• Glycogen Synthase Kinase 3

Topics

• Adult
• Alleles
• Case-Control Studies
• Female
• Genotype
• Glycogen Synthase Kinase 3 (genetics, pharmacology)
• Glycogen Synthase Kinase 3 beta
• Humans
• Male
• Middle Aged
• Polymorphism, Genetic
• Schizophrenia (genetics)
• Trinucleotide Repeats